Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion's AI-driven platform for chronic low back pain.

Program aims to follow successful reimbursement wins in the UK that are translating into sustained scan volume growth in step with reduced market access barriers

BROOMFIELD, Colo., June 09, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the launch of a Market Access Program in partnership with PRIA Healthcare.

This initiative represents a significant step in Aclarion's strategy to advance Nociscan®, the company's proprietary AI-driven platform for chronic low back pain, through the reimbursement process to expand patient access and ultimately support commercial adoption. The program reinforces Aclarion's commitment to supporting physicians, hospitals, and payers as they assess Nociscan's clinical and economic value in improving surgical decision-making and patient outcomes.